{
    "clinical_study": {
        "@rank": "112680", 
        "arm_group": [
            {
                "arm_group_label": "Picosecond Q-switched Laser Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser"
            }, 
            {
                "arm_group_label": "Nanosecond Q-switched Laser Treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the investigational medical grade laser device to a\n      marketed medical grade laser device for effectiveness in lightening or clearing unwanted\n      tattoos. This study will also compare any side effects from treatment with the devices."
        }, 
        "brief_title": "Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal", 
        "condition": "Tattoo Removal", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females or Males, 18 to 65 years of age (inclusive)\n\n          -  Fitzpatrick Skin Type I - IV (Appendix 3)\n\n          -  Tattoos containing black/blue ink alone or in combination with other colors\n\n          -  Target tattoos older than 1 year\n\n          -  Presence of tattoos equal or greater than 2 square inches, not to exceed 12 square\n             inches\n\n          -  Must be able to read, understand and sign the Informed Consent Form\n\n          -  Must be willing and able to adhere to the treatment and follow-up schedule and\n             post-treatment care instructions\n\n          -  Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun\n             exposure and use an approved sunscreen of SPF 50 or higher on the treated area\n             starting 2 to 4 weeks before the treatment and/or every day for the duration of the\n             study, including the follow-up period\n\n          -  Willing to use hydroquinone approximately 4 weeks pre-treatment and post- treatment\n             if required\n\n          -  Willingness to have digital photographs taken of the treated area\n\n          -  Agree not to undergo any other procedure(s) for the tattoo removal during the study\n\n          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of\n             birth control at least 3 months prior to enrollment and during the entire course of\n             the study\n\n        Exclusion Criteria:\n\n          -  Participation in a study of another device or drug within 6 months prior to\n             enrollment or during the study\n\n          -  Prior treatment for tattoo removal in the target area, e.g., with q-switched laser,\n             IPL, dermabrasion, electrocautery, cryotherapy\n\n          -  History of allergic reaction to pigments following tattooing\n\n          -  Presence of double tattoo in the treatment area\n\n          -  History of allergy to local anesthetics\n\n          -  History of allergy to topical antibiotics\n\n          -  History of malignant tumors in the target area\n\n          -  Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large\n             moles\n\n          -  Pregnant and/or breastfeeding\n\n          -  Having an infection, dermatitis or a rash in the treatment area\n\n          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,\n             e.g., uncontrolled hypertension\n\n          -  Suffering from coagulation disorders or taking prescription anticoagulation\n             medications\n\n          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing\n\n          -  History of immunosuppression/immune deficiency disorders or currently using\n             immunosuppressive medications\n\n          -  History of vitiligo, eczema, or psoriasis\n\n          -  History of connective tissue disease, such as systemic lupus erythematosus or\n             scleroderma\n\n          -  History of seizure disorders due to light\n\n          -  Any use of medication that is known to increase sensitivity to light, such as\n             tetracycline\n\n          -  History of herpes simplex and/or herpes zoster (shingles)\n\n          -  History of radiation to the treatment area or undergoing systemic chemotherapy for\n             the treatment of cancer\n\n          -  History of pigmentary disorders, particularly tendency for hyper- or\n             hypo-pigmentation\n\n          -  Systemic use of corticosteroid within 12 months of study participation\n\n          -  Use of oral isotretinoin within 12 months of study participation and topical use of\n             isotretinoin within 6 months on the treated area\n\n          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as\n             rheumatologic disease or lupus\n\n          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning\n             during the study\n\n          -  Current smoker or history of smoking within 6 months of study participation\n\n          -  As per the Investigator's discretion, any physical or mental condition which might\n             make it unsafe for the subject to participate in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973166", 
            "org_study_id": "C-13-TPS04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Picosecond Q-switched Laser Treatment", 
                "intervention_name": "Picosecond Q-switched Laser Treatment", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Nanosecond Q-switched Laser Treatment", 
                "intervention_name": "Nanosecond Q-switched Laser Treatment", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tattoo Removal", 
            "Q-switched laser", 
            "Nd:YAG laser", 
            "Nanosecond laser", 
            "Picosecond laser", 
            "Laser therapy", 
            "Tattoo", 
            "pulsed-laser", 
            "laser treatment", 
            "remove tattoo", 
            "tattoo clearing", 
            "tattoo lightening", 
            "tattoo lighten"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brisbane", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Split-tattoo Study Comparing Safety and Efficacy of Picosecond and Nanosecond Q-switched Nd:YAG Lasers for Tattoo Removal", 
        "overall_contact": {
            "email": "sbaker@cutera.com", 
            "last_name": "Shelby Baker", 
            "phone": "415-657-5749"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Tattoo clearing at 12 weeks post-final laser treatment for each treatment arm as assessed by blinded reviewers.", 
            "safety_issue": "No", 
            "time_frame": "12-weeks post-final laser treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tattoo clearing at 6 weeks post-final laser treatment for each treatment arm as assessed by blinded reviewers.", 
                "safety_issue": "No", 
                "time_frame": "6-weeks post-final treatment"
            }, 
            {
                "measure": "Tattoo clearing at 12  weeks post-final laser treatment for each treatment arm as assessed by the treating investigator.", 
                "safety_issue": "No", 
                "time_frame": "12-weeks post-final treatment"
            }, 
            {
                "measure": "Tattoo clearing at 12 weeks post-final treatment for each treatment arm as assessed by the subject", 
                "safety_issue": "No", 
                "time_frame": "12-weeks post-final treatment"
            }, 
            {
                "measure": "Subject discomfort during laser treatment for each treatment arm.", 
                "safety_issue": "Yes", 
                "time_frame": "at time of Laser treatment"
            }, 
            {
                "measure": "Subject satisfaction for each treatment arm at 12 weeks post-final laser treatment.", 
                "safety_issue": "No", 
                "time_frame": "12-weeks post-final laser treatment"
            }, 
            {
                "measure": "Incidence and severity of adverse device effects for each treatment arm during the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "12-weeks post-final laser treatment"
            }
        ], 
        "source": "Cutera Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cutera Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}